You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.

Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner ⊕⊕

found 2026 › Feb › 25 (Wed) @ 16:28 UTC

Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.